CNS Disorders Stocks
Biopharmaceutical firms in this sector focus on developing therapeutics for neurological and psychiatric conditions where high unmet clinical need meets complex regulatory hurdles. Revenue models center on proprietary drug delivery platforms and novel molecular targets for Alzheimer’s, clinical depression, and rare neurodegenerative disorders.
As of Oct 23, 2026, CNS Disorders has 98 US-listed companies worth $96.6B combined. The median member moved +1.4% over the past week; SPTX led among the 25 largest at +15.6% and RGC trailed at -20.0%.
Companies in CNS Disorders
- NBIX – Neurocrine Biosciences Inc, $14.6B
- AXSM – Axsome Therapeutics Inc, $7.6B
- ALKS – Alkermes Plc, $7.4B
- IONS – Ionis Pharmaceuticals Inc, $7.3B
- PRAX – Praxis Precision Medicines Inc, $7.2B
- RGC – Regencell Bioscience Holdings Ltd, $4.8B
- DFTX – Definium Therapeutics, Inc., $4.4B
- INDV – Indivior PLC Ordinary Shares, $4.2B
- XENE – Xenon Pharmaceuticals Inc, $3.5B
- ACAD – ACADIA Pharmaceuticals Inc, $3.5B
- DNLI – Denali Therapeutics Inc, $3B
- DYN – Dyne Therapeutics Inc, $2.9B
- SUPN – Supernus Pharmaceuticals Inc, $2.4B
- HRMY – Harmony Biosciences Holdings, $2.1B
- ZBIO – Zenas BioPharma, Inc. Common Stock, $1.8B
- STOK – Stoke Therapeutics Inc, $1.7B
- CMPS – Compass Pathways Plc, $1.6B
- KRSA – Korsana Biosciences, Inc., $1.5B
- TSHA – Taysha Gene Therapies Inc, $1.4B
- RAPP – Rapport Therapeutics, Inc. Common Stock, $1.3B
- LBRX – LB Pharmaceuticals Inc Common Stock, $1.2B
- LTGO – Latigo Biotherapeutics, Inc. Common Stock, $1.1B
- SPTX – Seaport Therapeutics, Inc. Common Stock, $986M
- ANRO – Alto Neuroscience, Inc., $956M
- HELP – Cybin Inc., $799M
- COLL – Collegium Pharmaceutical Inc, $701M
- AQST – Aquestive Therapeutics Inc, $579M
- DRUG – Bright Minds Biosciences Inc, $506M
- MPLT – MapLight Therapeutics, Inc. Common Stock, $458M
- DMAC – DiaMedica Therapeutics Inc, $449M
- OVID – Ovid Therapeutics Inc, $441M
- RLMD – Relmada Therapeutics Inc, $347M
- VNDA – Vanda Pharmaceuticals Inc, $273M
- CTNM – Contineum Therapeutics, Inc. Class A Common Stock, $266M
- LXEO – Lexeo Therapeutics, Inc. Common Stock, $217M
- CAMP – CAMP4 THERAPEUTICS CORPORATION, $215M
- ALEC – Alector Inc, $214M
- ACOG – Alpha Cognition Inc, $192M
- NGEN – NervGen Pharma Corp., $166M
- ABOS – Acumen Pharmaceuticals Inc, $143M
- AVXL – Anavex Life Sciences Corp, $121M
- VYGR – Voyager Therapeutics Inc, $117M
- NRXP – NRX Pharmaceuticals Inc, $113M
- NERV – Minerva Neurosciences Inc, $112M
- BDTX – Black Diamond Therapeutics Inc, $105M
- IMUX – Immunic Inc, $95.4M
- TNXP – Tonix Pharmaceuticals Holding Corp, $93.1M
- KZIA – Kazia Therapeutics Ltd ADR, $89.7M
- NMRA – Neumora Therapeutics, Inc., $89.4M
- CGTX – Cognition Therapeutics Inc, $89.1M
- NTHI – NeOnc Technologies Holdings, Inc. Common Stock, $79.2M
- PMN – ProMIS Neurosciences Inc., $74.3M
- MNOV – MediciNova Inc, $73.8M
- GANX – Gain Therapeutics Inc, $71.6M
- ATHE – Alterity Therapeutics Ltd, $66.8M
- CING – Cingulate Inc, $63.4M
- INMB – INmune Bio Inc, $53.6M
- LONA – LeonaBio, Inc., $49M
- CLNN – Clene Inc., $47M
- SER – Serina Therapeutics Inc, $45.5M
- ANVS – Annovis Bio Inc, $42.3M
- GRCE – Grace Therapeutics, Inc., $41M
- CRVO – CervoMed Inc., $35.4M
- FLNA – Filana Therapeutics, Inc., $34M
- MIRA – MIRA Pharmaceuticals, Inc. Common Stock, $28M
- ABVC – ABVC Biopharma Inc, $26.7M
- IGC – India Globalization Capital Inc, $25.4M
- AYTU – Aytu BioScience Inc, $21.3M
- PBM – Psyence Biomedical Ltd. Common Shares, $19.1M
- NEUP – Neuphoria Therapeutics Inc, $18.8M
- NCEL – NewcelX Ltd., $16.5M
- AIFF – Firefly Neuroscience, Inc., $16M
- KTTA – Pasithea Therapeutics Corp, $14M
- CNSY – Cerenome, Inc., $12.9M
- ANEB – Anebulo Pharmaceuticals Inc, $12.8M
- BIVI – Biovie Inc, $11.9M
- PASG – Passage Bio Inc, $11.9M
- AEON – AEON Biopharma, Inc., $11.6M
- VTGN – VistaGen Therapeutics Inc, $8.9M
- NKGN – NKGen Biotech, Inc. Common Stock, $7.8M
- CNSP – CNS Pharmaceuticals Inc, $7.8M
- ALZN – Alzamend Neuro Inc, $6.5M
- RVPH – Reviva Pharmaceuticals Holdings Inc., $6.5M
- ENVB – Enveric Biosciences Inc, $6.2M
- NRSN – Neurosense Therapeutics Ltd, $5.8M
- ADXN – Addex Therapeutics Ltd, $5.4M
- NXL – Nexalin Technology Inc., $3.8M
- JUNS – Jupiter Neurosciences, Inc. Common Stock, $3.4M
- CMND – Clearmind Medicine Inc. Common Shares, $3.3M
- SPRC – Scisparc Ltd, $2.6M
- SILO – Silo Pharma Inc, $2.5M
- BTAI – BioXcel Therapeutics Inc, $2.3M
- OGEN – Oragenics Inc, $1.9M
- PTIX – Protagenic Therapeutics, $1.4M
- PXMD – PaxMedica Inc. Common Stock, $88,385
- TRVN – Trevena Inc, $57,010
- VAXX – Vaxxinity Inc, $12,678
- VRPX – Virpax Pharmaceuticals Inc, $248